Sophie Godet
YOU?
Author Swipe
View article: Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM Open
View article: Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study Open
Not available.
View article: Pomalidomide-induced lung injury: A case report
Pomalidomide-induced lung injury: A case report Open
Rationale: Pomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma. Patient concerns: A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspn…
View article: P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 Open
Background: High risk (HR) cytogenetics remains of poor prognosis, particularly in the RRMM setting. IFM 2010-02, Pd in advanced HR RRMM, had demonstrated limited activity with no addition of a proteasome inhibitor (PI), and a good safety …
View article: Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial Open
Not available.
View article: A prognostic index predicting survival in transformed Waldenström macroglobulinemia
A prognostic index predicting survival in transformed Waldenström macroglobulinemia Open
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) and is usually associated with a poor prognosis. The objective of this study was to develop and valid…
View article: Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group
Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group Open
International audience
View article: Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO) Open
Novel drugs targeting B cell receptor (BCR) signaling, such as ibrutinib and idelalisib, have dramatically changed the outcome of patients with chronic lymphocytic leukemia (CLL), especially those with high-risk features. However, data fro…
View article: Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (<scp>FILO</scp>)
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (<span>FILO</span>) Open
Summary Histological transformation ( HT ) to diffuse large B‐cell lymphoma ( DLBCL ) is a rare and poorly reported complication of Waldenström macroglobulinaemia ( WM ). We performed a retrospective study of 77 WM patients with biopsy‐pro…